All posts by Joe Lindsay

CCNA Team 15: Gerontechnology and Dementia

“The gerontechnology team will capitalize on the creativity and inventiveness of Canadian clinical and social scientists, engineers, computer scientists, and industry to develop innovative technology solutions that support older adults with dementia. … Canadians stand to benefit from the results by being offered cost-effective technology-based solutions that support older adults across physical, social, and psychological domains. Canadian industry will benefit through increased research capacity and cross-sector collaboration that will boost its global competitiveness in the expanding gerontechnology sector.”

CCNA Team 3: Protein Misfolding in Neurodegeneration

“One commonality among [Parkinson’s, Frontotemporal dementia, ALS and Alzheimer’s disease] is neuron death. The location of neuron death determines the disease type. Another commonality is protein deposits in dying neurons. … The Chakrabartty Lab has created a tool called STOP, which we can use to identify important components of neurodegenerative diseases and we can then use to target potential therapies.”

CCNA Team 20: Issues for Dementia Care in Rural Populations

“Some questions we ask ourselves are how can we build a lasting model of family-centered dementia care that combines specialist expertise, the latest research evidence, and the existing skills of primary healthcare teams in effective chronic disease management? … So often it seems like we’re scrambling when it comes to a crisis. If we could support people from the get-go, I think they’d have a better quality of life.”

CCNA Team 2: Inflammation and Nerve Growth Factors

“The early, asymptomatic stage of Alzheimer’s disease (referred to as “pre-clinical AD”) should be responsive to disease modifying therapy. Our objective is to explore these early events in order to identify targets for AD diagnosis, prevention, and treatment. Given our significant preliminary findings, we are focusing our studies on inflammation and trophic factor metabolism, as the AD progresses from pre-clinical to clinical presentation.”

Canadian Consortium on Neurodegeneration in Aging (CCNA)

The Canadian Consortium on Neurodegeneration in Aging (CCNA), a national initiative aimed at tackling the growing onset of dementia and related illnesses and improving the lives of Canadians with these illnesses, as well as their families and caregivers, brings together over 340 top Canadian researchers in the field of neurodegenerative diseases of aging. The Canadian Institutes of Health Research (CIHR) talk about the importance of dementia research with Dr. Alain Beaudet, President of CIHR, Dr. Yves Joanette, CIHR Institute of Aging Scientific Director, Dr. Howard Chertkow, a cognitive neurologist and head of the CCNA, as well as Francine Poirier, daughter and caregiver of Mignonne Beaudin-Poirier, a person living with Alzheimer’s disease.